Heino runyorwa rweazvino anticancer zvinodhaka mumusika.
1) Epacadostat
Epacadostat is undoubtedly a bright star in the IDO field. The results of clinical trials show that the combination of IDO inhibitors and programmed death receptor 1 (PD-1) monoclonal antibody has some advantages over PD-1 alone. anti. Incyte has reached a cooperation agreement with the two giants of PD-1 monoclonal antibody Merck and BMS, and also extensively explored the combined function of Epacadostat and other immune checkpoint inhibitors. The indications also cover multiple cancer categories, but Incyte seems Not content with this, their every move has attracted much attention. Incyte purchased the global development and commercial rights of all indications of Macrogenis’ PD-1 monoclonal antibody drug MGA012 in October to further strengthen its PD-1 pipeline. It is believed that the combination of MGA012 and Epacadostat will soon begin.
2) Rova-T
Rova-T mushonga unorwisa hutachiona unonongedza puroteni yeDLL3 pamusoro pekenza maseru maseru. Iyo inoshandiswa yechipiri-mutsara wakasanganiswa kurapwa kwe kenza yemukomana mutsvuku uye ichiri muchikamu chekuyedza. AbbVie anotenda kuti Rova-T inosanganiswa neOpivoo kana Opdivo + Yervoy ichaita kuti ikunde mukenza diki yemukenza yemapapu, asi kwakawanda kuongororwa kwekiriniki kuchazodiwa kuratidza kubudirira kwayo.
3) ARN-509
Apalutamide (ARN-509) is a new generation of anti-androgen drugs developed for the treatment of prostate cancer. Johnson & Johnson has been quietly advancing the clinical development of apalutamide, and although these data have not been seen, it is also exciting to see it move towards regulatory agencies. With Johnson & Johnson’s strong business development team, this variety is expected to become a blockbuster drug.
4) Pertuzumab
As early as June 2012, Pertuzumab was approved by the FDA. It was used in combination with trastuzumab and docetaxel for metastatic breast cancer without anti-HER2 + therapy or chemotherapy. In September 2013, Pertuzumab was further approved by the FDA. It was used in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 + breast cancer. On December 20, 2017, the FDA approved the combination of Pertuzumab with Trastuzumab and chemotherapy for adjuvant treatment of patients with early-stage HER2 + breast cancer with a higher risk of recurrence. At the same time, the FDA changed Pertuzumab’s previous adjuvant therapy for HER2 + breast cancer from accelerated approval to full approval.
5) Opdivo
Opdivo ndeimwe yeanonyanyo shandiswa PD-1 mAbs mukiriniki yekuita, uye yakagamuchirwa neDFA yezviratidzo zvipfumbamwe. Chinyorwa cheOpdivo chekunyorera chechipiri-mutsara kurapwa kweasina-madiki maseru kenza yemapapu kuChina akagamuchirwa neCDE munaNovember 2, 2017, uye yakaverengerwa mukutanga kuongorora neCDE muna Zvita 18 nechikonzero chekuti ine "yakakosha kurapa zvakanakira zvichienzaniswa nemishonga iriko ”.
6) Thiopenfigrastin jekiseni
Thiofeigrastin jekiseni, 19K (HHPG-19K, polyethylene glycol recombinant human granulocyte inosimudzira chinhu jekiseni), inogona kushandiswa kiriniki kune neutropenia inosanganisirwa nekemotherapy mune vane tumarara varwere. 19K yakatumira kunyorera kunyorera (CXSS1300007) kutanga kwaKurume 4, 2013. Ichiona kuti yaive pamusika munguva pfupi, yakazowana kuzviongorora kwekiriniki musi waChikunguru 22, 2015. Musi waMay 18, 2016, Hengrui akaburitsa chiziviso. kubvisa iyo 19K yekunyorera kunyorera, uye ikati ichapedzisa inoenderana tsvagiridzo nekusimudzira dhata uye kuwedzera iyo application nekukurumidza sezvazvinogona. Musi waKurume 24, 2017, Hengrui akanyorera zvekare 19K zvinyorwa pasi pezita remushonga retiopefilgrastim jekiseni. Iyo yakamboonekwa muCDE nechikonzero che "pachena kurapwa mabhenefiti achienzaniswa nezviripo marapirwo uye makuru mapurojekiti". Izvo zvakarongerwa kuverengerwa mune yekutanga kuongorora runyorwa. Kunyangwe yaive isina kubatanidzwa mune yekupedzisira ongororo, iyo technical tekinoroji yakapedzwa muna Gumiguru 13, 2017, uye iri kumirira pane-saiti sosi. Kana ikabudirira, inotarisirwa kuwana mvumo yeCFDA muna 2018Q2.
7) Anlotinib
Anlotinib is a multi-target tyrosine kinase inhibitor, which can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit and other kinases. It has anti-tumor angiogenesis and inhibits tumor growth. It has obtained major national new drugs Special funding for creation. Anlotinib’s application for the treatment of non-small cell lung cancer was accepted by the CDE on March 16, 2017, and it took a special approval channel. On April 27, 2017, it had “significant treatment advantages compared with existing treatments”. The “major project” reason was included in the priority review by CDE. At present, the technical review of the pharmacology and toxicology and clinical parts has been completed, and the pharmacy part is queued for review. After that, it will enter the on-site inspection and issue a three-in-one report.
8) Pirlotinib
Pirlotinib is an EGFR / HER2 small molecule inhibitor, developed for the treatment of HER2 + breast cancer, gastric cancer and NSCLC, and has received special funding from the National Key New Drug Development Program. It is a new drug project that Hengrui has high hopes for. Hengrui submitted to CDE a conditional listing application for pirlotinib for breast cancer. The application was accepted by CDE on August 24, 2017, and it took a special approval channel. On September 26, 2017, it had a “significant clinical value, The “major project” reason was included in the priority review by CDE. At present, the technical review of the clinical part has been completed, and the pharmaceutical and pharmacological and toxicological parts are queued for review. It is expected that the CFDA will be approved in 2018Q2.
9) Fruquintinib
Fruquintinib idiki-morekuru VEGFR inhibitor yakazvimiririra yakagadziridzwa neHehuang Mushonga. Yakarongwa kugadzirwa kurapwa kwegomarara remukati, gomarara remudumbu, uye NSCLC. Chikumbiro cheFruquintinib chekurapa kenza yakakura yakagamuchirwa neCDE munaJune 30, 2017, uye yakabatanidzwa mukuongorora kwekutanga neCDE musi waSeptember 4, 2017 pamusana pekuti ine "yakakosha kukosha kwekliniki; mapurojekiti makuru". Parizvino, ongororo yehunyanzvi yechikamu chepharmacology uye toxicology yapedzwa, uye pharmacy nemitsetse yekiriniki yakamirira kuongororwa. Inotarisirwa kubvumidzwa neCFDA kunyorwa mu2018Q3.
10) Olapalli
Lynparza ndiyo yekutanga nyika PARP inhibitor inoenderana neiyo DNA kukuvara mhinduro (DDR) mashandiro. Yakatanga kubvumidzwa neDFA muna Zvita 2014 yechina-mutsara kurapwa kweiyo yepamusoro BRCA + kenza yeovari. Musi waChikunguru 17, gore rino, yakabvumidzwa neDFA kune yechipiri-mutsara yekurapa kurapwa mune varwere vane epithelial ovarian cancer, fallopian tube kenza, uye yekutanga peritoneal cancer iyo yakadzokazve mushure mekupindura kune platinum-based zvinodhaka. Parizvino, Lynparza akarapa varwere vanopfuura zviuru makumi matatu vane gomarara repamberi. Musi waGumiguru 30,000, AstraZeneca / Mercedon's Lynparza yakaendesa kune iyo FDA yekemotherapeutic germline BRCA mutation uye HER18-metastatic kenza yemazamu yekushambadzira application (sNDA) yakagamuchirwa neDFA uye yakawanikwa
kukoshesa kuongorora kukosha, zvinoshanda Ruzhinji rwunotarisirwa kuwedzera zvakanyanya.
11) Lenvatinib
Lemvatinib ine-multi-targeted kinase inhibitor iyo inogona kuvhara nhevedzano yezvinodzora zvinhu zvinosanganisira VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET mumamota masero. Musi waKukadzi 13, 2015, yakatenderwa neFDA semuongorori wepamberi uye mushonga wenherera wekushambadzira semushonga wepamusoro-njodzi wakasiyana wegomarara rethyroid refractory kune radioactive iodine. Chivabvu 13, 2016 yakabvumidzwa neFDA yakabatana neAfinitor kurapa advanced renal cell carcinoma neyakapfuura anti-VEGF therapy. Nezviratidzo zvegomarara rechiropa, Eisai akatumira chikumbiro chekushambadzira muJapan muna Chikumi 2017, akatumira chikumbiro chekushambadzira kuEMA neFDA muna Chikunguru 2017, uye akatumira chikumbiro chekushambadzira kuCFDA muna Mbudzi 3, 2017. Yakawanikwa muna Zvita 18, 2017 CDE yekutanga kuongorora. Iyo FDA yakapa nherera mushonga wekufanirwa nenvaltinib kurapa hepatocellular carcinoma. Yakagamuchira Eisai's sNDA munaGunyana 27, ikaita chibvumirano zvinoenderana nemwedzi gumi yekuongorora, iyo ichatenderwa pamberi pekupera kwaChikunguru.
12) Ceritinib
Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA on April 29, 2014 for crizotinib for intolerance or disease progression in ALK + non-small cell lung cancer, 2017. May 26 FDA approved first-line treatment for ALK + metastatic non-small cell lung cancer. Novartis’ ceritinib capsule listing application was formally accepted by the CDE on December 11, 2017. It should be included in the priority review later (clinical applications have received priority review). It is expected to be approved by the CFDA in 2018Q4. The above summarizes the latest drugs in the treatment of cancer. The drugs are widely used in lung cancer, gastric cancer, liver cancer, breast cancer, and ovarian cancer.
